Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Expected to Post Quarterly Sales of $4.39 Billion

Brokerages expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to announce $4.39 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $4.21 billion to $4.77 billion. Regeneron Pharmaceuticals reported sales of $2.42 billion during the same quarter last year, which indicates a positive year over year growth rate of 81.4%. The firm is expected to issue its next quarterly earnings report on Friday, February 4th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $15.22 billion for the current financial year, with estimates ranging from $13.44 billion to $15.89 billion. For the next financial year, analysts forecast that the business will report sales of $12.83 billion, with estimates ranging from $11.56 billion to $14.93 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, November 4th. The biopharmaceutical company reported $15.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.81 by $5.56. The firm had revenue of $3.45 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 50.38% and a net margin of 51.65%. The company’s revenue was up 50.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $7.68 earnings per share.

Several equities research analysts have recently weighed in on the company. Benchmark cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 5th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $653.00 price objective for the company. in a research report on Thursday, November 11th. BMO Capital Markets assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 19th. They issued an “outperform” rating and a $780.00 price objective for the company. Oppenheimer increased their price objective on Regeneron Pharmaceuticals from $725.00 to $825.00 and gave the company an “outperform” rating in a research report on Friday, August 6th. Finally, Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $700.00 to $760.00 and gave the company an “overweight” rating in a research report on Wednesday, November 10th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $703.59.

Shares of REGN traded down $1.14 during mid-day trading on Friday, hitting $648.18. The company’s stock had a trading volume of 545,233 shares, compared to its average volume of 850,101. Regeneron Pharmaceuticals has a one year low of $441.00 and a one year high of $686.62. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.16 and a current ratio of 3.71. The firm has a market capitalization of $69.71 billion, a PE ratio of 10.35, a price-to-earnings-growth ratio of 1.16 and a beta of 0.19. The stock’s 50-day moving average is $606.80 and its two-hundred day moving average is $588.14.

In other news, Director Joseph L. Goldstein sold 2,479 shares of the firm’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $650.00, for a total value of $1,611,350.00. Following the completion of the sale, the director now directly owns 8,370 shares in the company, valued at $5,440,500. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Friday, October 1st. The shares were sold at an average price of $576.75, for a total value of $576,750.00. The disclosure for this sale can be found here. Insiders have sold 46,079 shares of company stock valued at $30,010,914 over the last quarter. Corporate insiders own 11.84% of the company’s stock.

A number of institutional investors have recently bought and sold shares of REGN. Putnam Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 43.1% in the third quarter. Putnam Investments LLC now owns 1,342,754 shares of the biopharmaceutical company’s stock valued at $812,608,000 after acquiring an additional 404,567 shares during the last quarter. BlackRock Inc. boosted its holdings in Regeneron Pharmaceuticals by 3.7% in the third quarter. BlackRock Inc. now owns 9,366,862 shares of the biopharmaceutical company’s stock valued at $5,668,639,000 after acquiring an additional 333,312 shares during the last quarter. Amundi bought a new position in Regeneron Pharmaceuticals in the second quarter valued at about $112,501,000. Point72 Asset Management L.P. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at about $105,396,000. Finally, Sivik Global Healthcare LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $5,787,000. Institutional investors and hedge funds own 82.08% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Read More: Is the QQQ ETF safe?

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.